Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer
Public ClinicalTrials.gov record NCT00003327. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Trial of Paclitaxel (TAXOL) Administered as a Weekly One Hour Infusion in Previously Treated Patients With Advanced Head and Neck Cancer
Study identification
- NCT ID
- NCT00003327
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Theradex
- Industry
- Enrollment
- 60 participants
Conditions and interventions
Conditions
Interventions
- paclitaxel Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 1997
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Jul 23, 2008
Started 1997
United States locations
- U.S. sites
- 20
- U.S. states
- 15
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| California Cancer Center | Fresno | California | 93720 | — |
| Loma Linda University Medical Center | Loma Linda | California | 92354 | — |
| Memorial Regional Cancer Center at Memorial Regional Hospital | Hollywood | Florida | 33021 | — |
| Sylvester Cancer Center, University of Miami | Miami | Florida | 33136 | — |
| Savannah Hematology Oncology Associates | Savannah | Georgia | 31405 | — |
| Decatur Memorial Hospital Cancer Care Institute | Decatur | Illinois | 62526 | — |
| Mary Bird Perkins Cancer Center | Baton Rouge | Louisiana | 70809 | — |
| Maine Center for Cancer Medicine and Blood Disorders | Scarborough | Maine | 04074 | — |
| Johns Hopkins Oncology Center | Baltimore | Maryland | 21231-2410 | — |
| Kansas City Internal Medicine | Kansas City | Missouri | 64132 | — |
| Lourdes Regional Cancer Center | Binghamton | New York | 13905 | — |
| Saint Vincent Catholic Medical Center of New York | New York | New York | 10011 | — |
| Presbyterian Healthcare | Charlotte | North Carolina | 28233-3549 | — |
| Akron City Hospital | Akron | Ohio | 44309 | — |
| Medical Oncology Hematology Associates, Inc. | Dayton | Ohio | 45409 | — |
| Reading Hospital and Medical Center | Reading | Pennsylvania | 19612-6052 | — |
| Joe Arrington Cancer Research and Treatment Center | Lubbock | Texas | 79410-1894 | — |
| Cancer Care Institute of South Texas | San Antonio | Texas | 78229 | — |
| Danville Hematology and Oncology, Inc. | Danville | Virginia | 24541 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00003327, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 23, 2008 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00003327 live on ClinicalTrials.gov.